Traws Pharma Reports Q3 Results
Traws Pharma reported Q3 2026 financial results and highlighted positive Phase 2a final results for ratutrelvir and successful bridging studies for tivoxavir marboxil, supporting regulatory plans for PAXLOVID ineligible patients and Q4 resubmission.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed